[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Volume 24, Issue 1 (1-2026) ::
Int J Radiat Res 2026, 24(1): 173-178 Back to browse issues page
Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation for Refractory Systemic Sclerosis and Cancer Patients Undergoing Radiotherapy
S. Tong , Z. Liu , Q. Wen , X. Zhang , C. Zheng
Department of Hematology, Rheumatology and Immunology, Pu'er People's Hospital, Pu’er, China , onrx855@163.com
Abstract:   (37 Views)
Background: To evaluate the clinical effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) as a therapeutic approach for patients with both refractory systemic sclerosis (SSc) and cancer undergoing radiotherapy. Materials and Methods: Eleven patients with refractory SSc and concurrent cancer received Auto-HSCT following peripheral blood stem cell mobilization. Standardized radiotherapy protocols were applied based on cancer type. Preconditioning regimens included combinations of cyclophosphamide, melphalan, rituximab, and bendamustine. Post-transplant assessments focused on hematopoietic recovery, SSc disease activity, and tumor response. Results: A mean of 3.87 × 106/kg CD34+ cells were collected. All patients achieved hematopoietic reconstitution, with neutrophil and platelet recovery occurring in 9 ± 3 and 14 ± 7 days, respectively. At a median follow-up of 14.6 months, improvements in modified Rodnan skin scores (mRSS), digital ulcers, Raynaud’s phenomenon, and pulmonary fibrosis were observed. Eight patients showed sustained improvement in SSc and cancer response. Three patients relapsed and required additional immunotherapy. Conclusion: Auto-HSCT appears to be a feasible and effective option for patients with both refractory SSc and cancer undergoing radiotherapy. It improved autoimmune disease control, enhanced hematopoietic recovery, and supported cancer treatment with manageable toxicity.
Keywords: Systemic Sclerosis, Neoplasms, Radiotherapy, Hematopoietic Stem Cell Transplantation, Autologous, CD34 Antigen.
Full-Text [PDF 817 kb]   (4 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tong S, Liu Z, Wen Q, Zhang X, Zheng C. Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation for Refractory Systemic Sclerosis and Cancer Patients Undergoing Radiotherapy. Int J Radiat Res 2026; 24 (1) :173-178
URL: http://ijrr.com/article-1-6898-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 24, Issue 1 (1-2026) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.12 seconds with 50 queries by YEKTAWEB 4741